Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma

Academic Article

Publication Date:

2018

Iris type:

1.1 Articolo in rivista

Keywords:

lenalidomide; mantle cell lymphoma; non-Hodgkin lymphoma; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Recurrence; Retreatment; Thalidomide; Treatment Outcome; Hematology

List of contributors:

Arcaini, Luca; Lamy, Thierry; Walewski, Jan; Belada, David; Mayer, Jiri; Radford, John; Jurczak, Wojciech; Morschhauser, Franck; Alexeeva, Julia; Rule, Simon; Cabeçadas, José; Campo, Elias; Pileri, Stefano A.; Biyukov, Tsvetan; Patturajan, Meera; Casadebaig Bravo, Marie-Laure; Trnĕný, Marek

Authors of the University:

ARCAINI LUCA

Handle:

https://iris.unipv.it/handle/11571/1213712

Published in:

BRITISH JOURNAL OF HAEMATOLOGY

Journal

Overview

Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma

Arcaini, Luca; Lamy, Thierry; Walewski, Jan; Belada, David; Mayer, Jiri; Radford, John; Jurczak, Wojciech; Morschhauser, Franck; Alexeeva, Julia; Rule, Simon; Cabeçadas, José; Campo, Elias; Pileri, Stefano A.; Biyukov, Tsvetan; Patturajan, Meera; Casadebaig Bravo, Marie-Laure; Trnĕný, Marek

BRITISH JOURNAL OF HAEMATOLOGY

Overview

URL